Clinical trial / 2015
In healthy volunteers, 18 mg of quinine significantly reduced subsequent calorie intake and increased postprandial CCK release.
Twenty healthy volunteers randomly received an acid-resistant capsule containing either placebo or 18 mg of hydrochloride (HCl) quinine on 2 separate days, followed by an ad libitum meal 60 minutes later. Calorie intake was significantly lower with quinine compared to placebo (514 ± 248 vs 596 ± 286 kcal; P = 0.007). Higher CCK ΔT90 vs T0 and ΔT90 vs T60 were observed with quinine versus placebo (0.70 ± 0.69 vs 0.10 ± 0.86 ng/mL, P = 0.026; 0.92 ± 0.75 vs 0.50 ± 0.55 ng/mL, P = 0.033). The calorie reduction was significant in PTC tasters (526 ± 275 vs 659 ± 320 kcal; P = 0.005) but not in PTC non-tasters (499 ± 227 vs 519 ± 231 kcal; P = 0.525).
- Study type
- Double-blind randomized crossover study
- Who was studied
- 20 healthy volunteers
- What was measured
- Calorie intake during an ad libitum meal, plasma cholecystokinin (CCK), and ghrelin levels
THE PAPER
The Bitter Taste Receptor Agonist Quinine Reduces Calorie Intake and Increases the Postprandial Release of Cholecystokinin in Healthy Subjects.
Andreozzi P, Sarnelli G, Pesce M, Zito FP, Alessandro AD, Verlezza V, Palumbo I, Turco F, Esposito K, Cuomo R. J Neurogastroenterol Motil, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.